SCHEMBL2887963

SCHEMBL2887963

Cc1ccc(Sc2ccccc2C(C)C)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
NSD2 O96028 1/20 0.35
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 2/20 0.35
PTPN11 Q06124 2/20 0.34
USP1 O94782 1/20 0.34
WDR48 Q8TAF3 1/20 0.34
ITGB2 P05107 8/20 0.33
ICAM1 P05362 8/20 0.33
ITGAL P20701 8/20 0.33
DHFR P00374 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GABRA1 P14867 1/20 0.32
GABRB2 P47870 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5318161 0.78 L3MBTL1 (0.46) MEN1KMT2AICAM1DHFRNPC1
SCHEMBL2888693 0.75 GABRA1 (0.41) LMNANSD2SLC6A2SLC6A4DHFR
SCHEMBL30389926 0.74 GABRA1 (0.48) LMNASLC6A2ITGB2ICAM1ITGAL
SCHEMBL4808650 0.74 GABRA1 (0.48) LMNASLC6A2ITGB2ICAM1ITGAL
SCHEMBL5313607 0.73 CYP2C9 (0.51) MEN1LMNAKMT2ASLC6A2DHFR
SCHEMBL14113377 0.73 SLC6A4 (0.50) MEN1LMNAKMT2ASLC6A4DHFR
SCHEMBL4801714 0.70 MMP2 (0.52) MEN1KMT2ADHFR
SCHEMBL4800273 0.70 HTR1A (0.41) LMNASLC6A2ITGB2ICAM1ITGAL
SCHEMBL191108 0.69 ITGB2 (0.39) LMNAITGB2ICAM1ITGAL
SCHEMBL14959711 0.68 USP1 (0.52) USP1WDR48NPC1RAB9AGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683218-B2 Method for producing thioether compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-23 US disclosed
US-7683218-B2 Method for producing thioether compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-23 US disclosed
US-7683218-B2 Method for producing thioether compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-23 US disclosed
US-20080108823-A1 Method For Producing Thioether Compound MSD K.K. (JP) 2008-05-08 US disclosed
US-20080108823-A1 Method For Producing Thioether Compound MSD K.K. (JP) 2008-05-08 US disclosed
US-20080108823-A1 Method For Producing Thioether Compound MSD K.K. (JP) 2008-05-08 US disclosed
EP-1806337-A1 METHOD FOR PRODUCING THIOETHER COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-07-11 EP disclosed
EP-1806337-A1 METHOD FOR PRODUCING THIOETHER COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108823-A1 Method For Producing Thioether Compound TST, MPST, PPIP5K2 MEN1 2589/4885LMNA 4839/4885KMT2A 1791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.